arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

BIOTRICITY INC.

BTCY
Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
53 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
43
Health
Weak
Bearish
auto_awesome

Analytical Summary

BIOTRICITY INC. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 14.8%
Op. Margin 16.3%
ROIC -1.6%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.25M
↑ +14.8%
Net Income Profit after all expenses
$-324.18K
↑ +83.3%
Operating Margin Operating profit as % of sales
16.3%
↑ +47.8% 70th
FCF / Share Free cash flow per share
$-0.03
↓ -272.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
31
Returns
56
Financial Health
48
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 53 quarters